文献速递炎症性肠病

确定炎症性肠病患者使用皮下抗肿瘤坏死因子药物的最佳依从性阈值

Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases.
PubMed 文献 · Am J Gastroenterol · 2017-12-12

该研究分析2009至2013年Truven Health MarketScan商业理赔数据库中6048例使用阿达木单抗(ADA,n=5325)或赛妥珠单抗(CZP,n=723)的炎症性肠病(IBD)患者,用药物持有率(MPR)评估依从性。ADA最佳MPR为0.86、CZP为0.87,高于此水平的患者疾病发作风险分别降低25%(HR 0.75,95%CI 0.67-0.83,P<0.01)和41%(HR 0.59,95%CI 0.46-0.76,P<0.01)。

要点

  • ADA最佳MPR阈值为0.86,CZP为0.87,24%患者低于该水平。
  • 高于阈值者ADA发作风险降低25%(HR 0.75,95%CI 0.67-0.83,P<0.01)。
  • 高于阈值者CZP发作风险降低41%(HR 0.59,95%CI 0.46-0.76,P<0.01)。

核心结论

  • 使用皮下生物制剂平均每2周延迟 refill 超过2天的患者疾病发作风险显著增加。
  • 需要进一步研究以改善那些持续延迟用药患者的依从性。

研究设计与样本

  • 分析2009至2013年Truven Health MarketScan商业理赔与 encounters 数据库中处方阿达木单抗(ADA)和赛妥珠单抗(CZP)的IBD患者理赔数据。
  • 共纳入6048例患者,其中ADA组5325例、CZP组723例;平均年龄41岁(±15),女性占54%。
  • 从起始用药至疾病发作计算药物持有率(MPR),疾病发作定义为用药起始90天后任何住院或新开激素处方。
  • 采用对数秩检验确定最佳MPR,并用多变量Cox比例风险比评估最佳MPR与发作的关联。

主要发现

  • ADA的最佳MPR为0.86,CZP为0.87;24%的患者低于该水平。
  • 调整起始时年龄、性别和合并用药后,依从性高于上述阈值的ADA患者发作风险降低25%(HR 0.75,95%CI 0.67-0.83,P<0.01)。
  • 调整起始时年龄、性别和合并用药后,依从性高于上述阈值的CZP患者发作风险降低41%(HR 0.59,95%CI 0.46-0.76,P<0.01)。

关键数值与推荐

  • ADA最佳MPR阈值为0.86;CZP最佳MPR阈值为0.87。
  • ADA依从性高于阈值者发作风险HR 0.75(95%CI 0.67-0.83,P<0.01)。
  • CZP依从性高于阈值者发作风险HR 0.59(95%CI 0.46-0.76,P<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In patients with inflammatory bowel disease (IBD) using biological therapy, non-adherence leads to anti-drug antibody formation and reduced effectiveness. Little is known about the optimal level of adherence in IBD patients on biologic therapy. We aimed to identify the association between adherence and disease flare and determine an optimal level of adherence. METHODS: We analyzed claims data for IBD patients prescribed adalimumab (ADA) and certolizumab (CZP) from the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013. Adherence was calculated using the medication possession ratio (MPR) from initiation until flare occurrence. A disease flare was defined as any hospitalization or new steroid prescription>90-days after drug initiation. The optimal MPR was determined using log-rank testing. The association between the optimal MPR and flare was assessed using multivariable Cox-Proportional hazards ratio. RESULTS: There were 6,048 patients who were prescribed ADA (n=5,325) or CZP (n=723) for IBD. The average age was 41 years (±15) and 54% were female. The optimal MPR identified was 0.86 for ADA and 0.87 for CZP; 24% of the patients were below this level. Adjusting for age, gender, and concomitant medications at initiation, patients who were adherent above these levels had a 25% lower risk of flare for ADA (HR: 0.75, 95%CI: 0.67-0.83, P<0.01) and 41% lower risk for CZP (HR: 0.59, 95%CI: 0.46-0.76, P<0.01). CONCLUSIONS: Patients who delay refills >2 days on average every 2 weeks of their subcutaneous biologics have significantly increased risk of flare. Further studies to improve adherence among those patients who consistently delay medication use are necessary.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Govani SM, Noureldin M, Higgins PDR, et al. Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. Am J Gastroenterol. 2017. PMID: 29231192. doi:10.1038/ajg.2017.438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。